AstraZeneca Sees 60% of China Sales From New Drugs in Five Years

(Bloomberg) -- AstraZeneca Plc expects new and innovative treatments to contribute 60% of its China revenue by 2024, up from just a fraction now, as the country’s push to bring novel therapies fast...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.